Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Electromed's earnings report shows strong financial performance with a 10% revenue growth and a 20% increase in net income, supported by improved gross margins and operational efficiencies. Despite a slight increase in operating expenses, the company's financial health remains robust with increased cash flow. The absence of negative insights from the Q&A session further supports a positive outlook. These factors suggest a likely positive stock price movement over the next two weeks.
Revenue Electromed reported revenue of $12.5 million for Q3 2026, representing a 10% increase year-over-year. This growth was driven by higher sales volume and improved reimbursement rates.
Gross Margin The gross margin for the quarter was 72%, up from 70% in the same period last year. The improvement was attributed to better operational efficiencies and cost management.
Net Income Net income for Q3 2026 was $1.8 million, a 20% increase compared to the prior year. This was due to higher revenue and controlled operating expenses.
Operating Expenses Operating expenses were $6.5 million, up 5% year-over-year. The increase was primarily due to investments in sales and marketing initiatives.
Cash Flow from Operations Cash flow from operations was $2.3 million, a 15% increase year-over-year, driven by improved profitability and efficient working capital management.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
Electromed's earnings report shows strong financial performance with a 10% revenue growth and a 20% increase in net income, supported by improved gross margins and operational efficiencies. Despite a slight increase in operating expenses, the company's financial health remains robust with increased cash flow. The absence of negative insights from the Q&A session further supports a positive outlook. These factors suggest a likely positive stock price movement over the next two weeks.
The earnings report shows strong financial metrics with revenue, operating income, and EPS all increasing significantly. The company's strategic focus on expanding its sales force and product awareness has paid off, particularly in the homecare segment. The approval of a stock repurchase plan and actual buybacks signal confidence in future prospects. While SG&A expenses have risen, the overall financial health remains robust. The Q&A session highlighted growth opportunities and strategic initiatives. Despite minor concerns about rep productivity, the strong financial performance and strategic initiatives suggest a positive stock price movement.
The earnings call highlights strong financial performance with a 15% revenue increase and 38% rise in operating income. The strategic expansion of sales territories and focus on the bronchiectasis market are promising. The $10 million stock repurchase program indicates confidence in the company's value. However, economic uncertainties and unclear management responses about hospital sales create slight concerns. Overall, the sentiment is positive due to strong growth metrics, strategic initiatives, and shareholder returns.
The earnings call highlights strong financial performance, with significant revenue and net income growth, improved gross margins, and efficient cash management. Positive developments include successful sales team expansion, effective CRM implementation, and promising hospital channel growth. The Q&A section reveals favorable analyst sentiment and market expansion opportunities, despite some management vagueness. The company's proactive strategies, including share repurchases and manufacturing optimization, support a positive outlook. Overall, the combination of strong earnings, optimistic guidance, and strategic initiatives suggests a positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.